AFJOG

African Journal of Obstetrics and Gynaecology | Volume 2 | Issue 2 | 2024 | 22 *vs.onceweeklyalendronate BMD=BoneMineralDensity References:1. Boniva®150mg tabletsapprovedprofessional information,5March2009. 2. DepartmentofHealth.DatabaseofMedicinePricesSeptember2022. [Accessed13September2022].Availableat:http://www.mpr.gov.za/PublishedDocuments.aspx#DocCatId=21. 3. HarrisST,Reginster J-Y,HarleyC, etal. Riskoffracture inwomentreatedwithmonthlyoral ibandronateorweeklybisphosphonates:TheeValuationof IBandronateEfficacy(VIBE)databasefracturestudy. Bone 2009;44:758-765. 4. MillerPD,ReckerRR,HarrisS, etal. Long-termfractureratesseenwithcontinued ibandronate treatment: pooled analysis of DIVA and MOBILE long-term extension studies. Osteoporos Int 2014;25:349-357. 5. Miller PD, Recker RR, Reginster J-Y, et al. Efficacy of monthly oral ibandronate is sustained over 5 years: the MOBILE long-term extension study. Osteoporos Int 2012;23:1747-1756. 6. CottéFE,FardelloneP,MercierF,GaudinAF,RouxC.Adherence tomonthlyandweeklyoralbisphosphonates inwomenwithosteoporosis. Osteoporos Int .2010;21(1):145-155.doi:10.1007/s00198-009-0930-1. 7. HadjiP,MinneH,PfeiferM, etal .Treatmentpreference formonthlyoral ibandronate andweeklyoralalendronate inwomenwithpostmenopausalosteoporosis:A randomized,crossoverstudy (BALTO II). JointBoneSpine .2008;75:303-310.doi:10.1016/j.jbspin.2007.07.011. 8. CooperA,Drake J,BrankinE;onbehalfofPERSIST Investigators.Treatmentpersistencewithonce-monthly ibandronateandpatient supportvs.once-weeklyalendronate: results from thePERSIST study. Int JClinPract .2006;60(8):896-905.doi:10.1111/j.1742-1241.2006.01059.x. www.adcockingramrx.co.za Once monthly Oral Once Monthly Oral Bisphosphonate 1,2 Lower risk of vertebral fractures vs. weekly bisphosphonates 3 • Sustained low clinical fracture rate over 5 years of treatment 4 • Maintained lumbar spine BMD with further gradual increases up to 5 years 5 • Well-tolerated with a proven 5-year safety profile 5 • Increased patient persistence and preference may contribute to improved fracture protection * 6-8 The first once monthly tablet for postmenopausal osteoporosis 1,2 BONIVA® 3 mg/3 ml injection. Each pre-filled syringe (3 ml) contains ibandronic acid 3 mg (as ibandronate monosodium salt, monohydrate). Reg. No. 41/3.2/0526. BONIVA® 150 mg tablet. Each tablet contains 150 mg ibandronic acid (as ibandronic sodium monohydrate). Reg.No.41/3.2/0527.For fullprescribing information refer to theprofessional informationapprovedby themedicines regulatoryauthority. Adcock IngramLimited.Co.Reg.No.1949/034385/06.PrivateBagX69,Bryanston,2021,SouthAfrica.CustomerCare:0860ADCOCK /232625.www.adcock.com.2022100710233483.October2022.